SAN DIEGO – February 13, 2012 – Animal Cell Therapies (ACT), a company specializing in veterinary diagnostics and cell-based therapies, today announced that its stem cell inventory is valued at more than $6 million. The evaluation, conducted by Cheetahlink and Capital Consulting Services, demonstrates the importance of this first step in the company’s mission to improve and extend the lives of dogs through innovative stem cell products and services.
When Animal Cell Therapies was created, the company partnered with a select group of researchers, scientists and collaborators from the U.S. and abroad to create an in-house program to grow and expand well-characterized animal stem cells in a scientific setting. The company’s founder, Dr. Kathryn Petrucci, recognized that in order to provide pure, potent, reliable, pathogen-free animal stem cells, ACT must optimize stem cell storage while improving stem cell transportation procedures and delivery techniques.
“This valuation essentially validates that the foundation we’ve set for this company – in the creation and maintaining of this stem cell inventory – is sound and will support the next steps in our strategy,” said Adam Irving, chief executive officer of Animal Cell Therapies. “Our capabilities are far reaching with broad applications.”
In maintaining its stem cell inventory, Animal Cell Therapies conducts specific cell assays, characterization processes and procedures to assess potential toxicity and consistently assure safety, purity, potency and a stable finished stem cell product or stem cell derivative. In addition, Animal Cell Therapies monitors processes with standardized, rigorous quality control specifications and testing parameters.
About Animal Cell Therapies
Founded in January 2008 in San Diego, California, Animal Cell Therapies (ACT) is the manifestation of veterinarian, Dr. Kathryn Petrucci, whose vision is to improve the lives of animals through thoughtful research and development, innovation and strategic partnerships. At the Company’s California-based stem cell research and development facility, the ACT team is focused on developing and delivering revolutionary cellular treatment and services to their customers. For more information, visit www.actcells.com.